LICENSE AGREEMENTLicense Agreement • March 15th, 2004 • Genvec Inc • Pharmaceutical preparations • New York
THIS LICENSE AGREEMENT (the “Agreement”), effective as of February 1, 1998 (the “Effective Date”), is entered by and between Asahi Chemical Industry Co., Ltd., with a principal place of business at 5-13, Shibaura 4-Chome, Minato-ku Tokyo, 108, Japan (“Asahi”), and GenVec, Inc. with a principal place of business at 12111 Parklawn Drive, Rockville, Maryland (“GenVec”).
GENVEC, INC. INDEMNIFICATION AND ADVANCEMENT OF EXPENSES AGREEMENTIndemnification & Liability • March 15th, 2004 • Genvec Inc • Pharmaceutical preparations • Delaware
This Agreement (“Agreement”) is entered into as of this 10 day of December, 2003 by and between GenVec, Inc., a Delaware corporation (the “Company”) and (“Indemnitee”).
PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT—EXCLUSIVE COVER PAGEPatent License Agreement • March 15th, 2004 • Genvec Inc • Pharmaceutical preparations • District of Columbia
This Patent License Agreement, hereinafter referred to as the AGREEMENT consists of this Cover Page, an attached AGREEMENT, a Signature Page, Appendix A (List of Patent(s) and/or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Modifications), Appendix E (Benchmarks), and Appendix F (Commercial Development Plan). The Parties to this AGREEMENT are:
Research Collaboration AgreementResearch Collaboration Agreement • March 15th, 2004 • Genvec Inc • Pharmaceutical preparations • New York
This Research Collaboration Agreement (the “Agreement”) is made effective as of the last date of the signatures below written (the “Effective Date”) between Cordis Corporation, a Florida corporation, with an address at 7 Powderhorn Drive, Warren, NJ 07059 (“Cordis”) and GenVec Inc., a Delaware corporation, with an address at 65 West Watkins Mill Road, Gaithersburg, MD 20878 (“GenVec”). Cordis will supply NOGA Guided Myostar catheters to GenVec. GenVec desires to use such Device for research purposes as described in the attached draft clinical protocol outline (Appendix A) or as otherwise provided in this Agreement.
